SEC61A1 and Buruli ulcer disease: Mycolactone is generally considered to be anti-inflammatory due the macroscopic appearance of Buruli ulcer, and mycolactone’s strong inhibitory effect on the production of SEC61-dependent cytokines and chemokines, as well as immune cell surface receptors [7,11,58].